We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Biomarker Predicts Potential Benefit of Checkpoint Inhibitor Therapy for Brain Cancer Patients

By LabMedica International staff writers
Posted on 06 Dec 2021
Print article
Image: Model of the PD-1 (Programmed cell death protein 1) protein. Only a subset of recurrent glioblastomas respond to anti-PD-1 immunotherapy (Photo courtesy of Wikimedia Commons)
Image: Model of the PD-1 (Programmed cell death protein 1) protein. Only a subset of recurrent glioblastomas respond to anti-PD-1 immunotherapy (Photo courtesy of Wikimedia Commons)
A phosphorylated form of ERK (extracellular signal-regulated kinase) protein has been identified as a biomarker that may be used to predict which brain cancer patients might benefit from checkpoint inhibitor therapy.

Checkpoint inhibitor therapy (PD-1 immune checkpoint blockade) is a form of cancer treatment immunotherapy, which targets immune checkpoints, key regulators of the immune system that stimulate or inhibit its actions. Tumors can use these checkpoints to protect themselves from attacks by the immune system. Checkpoint therapy can block inhibitory checkpoints, restoring immune system function. However, most cancer patients either do not respond to immune checkpoint blockade or develop resistance to it, often because of acquired mutations that impair antigen presentation.

In this regard, only a subset of recurrent glioblastoma (rGBM) responds to anti-PD-1 immunotherapy. This cancer comprises about 30% of all brain tumors and central nervous system tumors, and 80% of all malignant brain tumors. These tumors are heavily infiltrated with immune cells of myeloid origin.

Investigators at Northwestern University (Chicago, IL, USA) examined whether activation of the MAPK/ERK signaling pathway was associated with response to PD-1 inhibition in rGBM.

Results of this study revealed that immunohistochemistry for ERK1/2 phosphorylation (p-ERK), a marker of MAPK/ERK pathway activation, was predictive of overall survival following adjuvant PD-1 blockade in two independent rGBM patient cohorts. Furthermore, single-cell RNA-sequencing and multiplex immunofluorescence analyses revealed that p-ERK was mainly localized in tumor cells. GBMs were found to contain tumor-infiltrating myeloid cells and microglia with elevated expression of MHC class II and associated genes. These findings indicated that ERK1/2 activation in rGBM was predictive of response to PD-1 blockade and was associated with a distinct myeloid cell phenotype.

“This is an important breakthrough for patients who have not had an effective treatment in the cancer drug arsenal available to them,” said senior author Dr. Adam Sonabend, associate professor of neurosurgery at Northwestern University. “It might ultimately influence the decision on how to treat glioblastoma patients and which patients should get these drugs to prolong their survival.”

The study was published in the November 29, 2021, online edition of the journal Nature Cancer.

Related Links:
Northwestern University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.